Artiva Biotherapeutics appoints Thad Huston as CFO effective Feb 18, 2026

Artiva Biotherapeutics, Inc.

Thad Huston appointed CFO, principal financial and accounting officer, effective Feb 18, 2026.
Salary $540,000; discretionary annual cash bonus target of 40% of base salary.
Inducement award of 220,000 RSUs vesting 25% Feb 15, 2027, then quarterly over three years.
Severance: 9 months base salary (non-CIC) or 12 months + full target bonus (CIC), plus COBRA and accelerated vesting.
Huston previously CFO/COO at Galapagos NV and held senior roles at Kite Pharma, LivaNova, and Johnson & Johnson.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.